Pannu points to over $8B in upfront FGF21 deals and 500+ assets in development, and says the commercial and clinical split is arriving unusually early.
Recap by typeshit. Post by Andrew Pannu on X.
General exercise advice aimed at GLP-1 users, shared on Facebook with no study or expert named in the material available.
Gilead takes global rights to the Shanghai biotech's program, led by HCXT-2001, an oral peptide that could compete with injected IBD drugs.
A Facebook promo for a podcast episode on the ripple effects of GLP-1 consumers across businesses. Few details beyond the pitch.
10:49
xitsnemox posts a short check-in from week 14 on oral Wegovy, two weeks after stepping up to the 25mg tablet. A personal account, not medical advice.
A shared research summary evaluating how GLP-1 receptor agonists affect deaths and hospital stays in people with type 2 diabetes. Details are thin here.
Medical Xpress covers an implant approach to type 2 diabetes that uses a small catalyst to bring glucose down. Not a peptide or GLP-1 story.
Loading…